GenFleet Therapeutics (Shanghai) Inc.

劲方医药科技（上海）股份有限公司

02595.HK

Develops oncology and autoimmune drug candidates, including KRAS inhibitors, for solid tumor treatment in China and globally. Its lead product fulzerasib was China's first and the world's third approved KRAS G12C inhibitor, with a pipeline of eight candidates.

Filings

The documents are on HKEXnews; we link to the originals.

Matters the filing discloses

From the company’s latest filing; open a kind of matter to see how other companies disclosed it.

• Customer concentration
• Supplier concentration
• Reliance on platforms, partners or licences
• Outsourced production (OEM / contract manufacturing)
• Key long-term agreements
• Losses and path to profitability
• Net current liabilities or net liabilities
• Negative operating cash flow
• Cash burn and runway
• Working capital: receivables, prepayments and cash cycle
• Preferred shares and fair-value liabilities
• Adverse change after the track record
• Related-party transactions and balances
• Chapter 18A biotech